These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 36418079)

  • 1. [Shortages of Prescription Drugs Due to Compliance and Quality Issues in Japan].
    Izutsu KI; Abe Y; Kurita M; Yoshida H
    Yakugaku Zasshi; 2023 Feb; 143(2):139-152. PubMed ID: 36418079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generic Drug Shortage in Japan: GMP Noncompliance and Associated Quality Issues.
    Izutsu KI; Ando D; Morita T; Abe Y; Yoshida H
    J Pharm Sci; 2023 Jul; 112(7):1763-1771. PubMed ID: 36965844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Institutional barriers and enablers to implementing and complying with internationally accepted quality standards in the local pharmaceutical industry of Pakistan: a qualitative study.
    Tauqeer F; Myhr K; Gopinathan U
    Health Policy Plan; 2019 Jul; 34(6):440-449. PubMed ID: 31302684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Competition And Vulnerabilities In The Global Supply Chain For US Generic Active Pharmaceutical Ingredients.
    Socal MP; Ahn K; Greene JA; Anderson GF
    Health Aff (Millwood); 2023 Mar; 42(3):407-415. PubMed ID: 36791331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coping with drug shortages: A study of government-enterprise option cooperation stockpiling strategies for drugs in shortage considering API surrogate stockpiling subsidies.
    Lan Y; Meng C; Sun L; Huang Z
    PLoS One; 2024; 19(7):e0305383. PubMed ID: 38954737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Creating an Assessment Indicator of Quality Culture Development in the Generic Pharmaceutical Industry in Japan.
    Takahashi S; Takarada T; Kitamura R; Shikano M; Sakurai S
    PDA J Pharm Sci Technol; 2024 Feb; 78(1):45-69. PubMed ID: 37848202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug shortages. Part 2: Trends, causes and solutions.
    Aronson JK; Heneghan C; Ferner RE
    Br J Clin Pharmacol; 2023 Oct; 89(10):2957-2963. PubMed ID: 37455465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Corporate Characteristics and Adoption of Good Manufacturing Practice for Dietary Supplements in Japan.
    Sato K; Kodama K; Sengoku S
    Int J Environ Res Public Health; 2020 Jul; 17(13):. PubMed ID: 32630326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Draft Guideline for Industry to Manage Drug Shortages in Japan.
    Mamiya H; Izutsu KI; Mitani D
    Ther Innov Regul Sci; 2024 Jul; ():. PubMed ID: 39048765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors associated with drug shortages in Canada: a retrospective cohort study.
    Zhang W; Guh DP; Sun H; Lynd LD; Hollis A; Grootendorst P; Anis AH
    CMAJ Open; 2020; 8(3):E535-E544. PubMed ID: 32873582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of Drug Shortages and Association with Generic Drug Prices: A Retrospective Cohort Study.
    Dave CV; Pawar A; Fox ER; Brill G; Kesselheim AS
    Value Health; 2018 Nov; 21(11):1286-1290. PubMed ID: 30442275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The French reporting system for drug shortages: description and trends from 2012 to 2018: an observational retrospective study.
    Benhabib A; Ioughlissen S; Ratignier-Carbonneil C; Maison P
    BMJ Open; 2020 Mar; 10(3):e034033. PubMed ID: 32139487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug shortages in Israel: regulatory perspectives, challenges and solutions.
    Schwartzberg E; Ainbinder D; Vishkauzan A; Gamzu R
    Isr J Health Policy Res; 2017; 6():17. PubMed ID: 28392910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Active pharmaceutical ingredients for antiretroviral treatment in low- and middle-income countries: a survey.
    Fortunak JM; de Souza RO; Kulkarni AA; King CL; Ellison T; Miranda LS
    Antivir Ther; 2014; 19 Suppl 3(0 3):15-29. PubMed ID: 25310430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimation of total prescription weights of active pharmaceutical ingredients in human medicines based on a public database for environmental risk assessment in Japan.
    Sato K; Watanabe H; Ikeda T; Miida H; Ohtaki K; Watanabe K
    Regul Toxicol Pharmacol; 2018 Nov; 99():98-104. PubMed ID: 30223071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overview of "The Study in Risk-Based Manufacturing Environmental Control for Non-Sterile Drug Products".
    Shirokizawa O; Inoue K; Kamikukita T
    PDA J Pharm Sci Technol; 2021; 75(6):490-505. PubMed ID: 33990419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Causes of drug shortages in the legal pharmaceutical framework.
    De Weerdt E; Simoens S; Hombroeckx L; Casteels M; Huys I
    Regul Toxicol Pharmacol; 2015 Mar; 71(2):251-8. PubMed ID: 25591547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Critical drug shortages: implications for emergency medicine.
    Mazer-Amirshahi M; Pourmand A; Singer S; Pines JM; van den Anker J
    Acad Emerg Med; 2014 Jun; 21(6):704-11. PubMed ID: 25039558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reasons for supply side driven drug shortages - A mixed-methods study on first-level, higher-level, and root causes from the perspective of marketing authorization holders.
    Bade C; Olsacher A; Boehme P; Truebel H; Fehring L
    Res Social Adm Pharm; 2023 Aug; 19(8):1218-1227. PubMed ID: 37225602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug shortages: Implications for medical toxicology.
    Mazer-Amirshahi M; Hawley KL; Zocchi M; Fox E; Pines JM; Nelson LS
    Clin Toxicol (Phila); 2015 Jul; 53(6):519-24. PubMed ID: 25951876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.